| Chapter title |
Introduction: How We Encountered TCTP and Our Purpose in Studying It
|
|---|---|
| Chapter number | 1 |
| Book title |
TCTP/tpt1 - Remodeling Signaling from Stem Cell to Disease
|
| Published in |
Results and problems in cell differentiation, January 2017
|
| DOI | 10.1007/978-3-319-67591-6_1 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-967590-9, 978-3-31-967591-6
|
| Authors |
Adam Telerman, Robert Amson |
| Abstract |
In this brief introduction, we describe our encounter with TCTP. Back in 2000, we discovered TCTP in two quite different ways: first, we looked at protein partners of TSAP6 and one of them was TCTP. Then, in collaboration with Sidney Brenner, we performed a high-throughput differential screening comparing the parental cancer cells with revertants. The results indicated that TCTP was of the most differentially expressed genes. These two approaches were carried out only months apart. They guided our research and led to the discoveries of drugs that inhibit the function of TCTP. Much of the preclinical data on sertraline as an inhibitor of TCTP in cancer were obtained with Judith Karp at Johns Hopkins. This drug is now given in combination with Ara-C to patients in a phase I clinical trial for Acute Myeloid Leukemia. We will here detail how all this happened in our lab while working around one central project: tumor reversion. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 7 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 1 | 14% |
| Student > Bachelor | 1 | 14% |
| Student > Doctoral Student | 1 | 14% |
| Student > Master | 1 | 14% |
| Unknown | 3 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 2 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 14% |
| Immunology and Microbiology | 1 | 14% |
| Unknown | 3 | 43% |